{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:13:25Z","timestamp":1784981605096,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.pbb.2022.173404","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T21:41:48Z","timestamp":1652478108000},"page":"173404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes"],"prefix":"10.1016","volume":"217","author":[{"given":"Laura E.","family":"Hawley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Prochaska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Goodlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2022.173404_bb0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nbd.2005.12.006","article-title":"DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects","volume":"22","author":"Ahn","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173404_bb0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/fampra\/cmaa097","article-title":"Burden of family caregivers of down syndrome children: a cross-sectional study","volume":"38","author":"Alam El-Deen","year":"2021","journal-title":"Fam. Pract."},{"key":"10.1016\/j.pbb.2022.173404_bb0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jneumeth.2008.05.003","article-title":"The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting","volume":"172","author":"Aldridge","year":"2008","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.pbb.2022.173404_bb0020","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/hmg\/10.18.1915","article-title":"Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome","volume":"10","author":"Altafaj","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.pbb.2022.173404_bb0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.braindev.2017.10.001","article-title":"Developmental trend of children with Down's syndrome - how do sex and neonatal conditions influence their developmental patterns?","volume":"40","author":"Aoki","year":"2018","journal-title":"Brain Dev."},{"key":"10.1016\/j.pbb.2022.173404_bb0030","article-title":"Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1\/Yey mouse models of Down syndrome","volume":"11","author":"Aziz","year":"2018","journal-title":"Disease Models & Mechanisms"},{"key":"10.1016\/j.pbb.2022.173404_bb0035","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1590\/1413-812320172211.31102016","article-title":"Burden of caregivers of children and adolescents with Down Syndrome","volume":"22","author":"Barros","year":"2017","journal-title":"Cien. Saude Colet."},{"key":"10.1016\/j.pbb.2022.173404_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/hmg\/9.2.195","article-title":"Discovery and genetic localization of down syndrome cerebellar phenotypes using the Ts65Dn mouse","volume":"9","author":"Baxter","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.pbb.2022.173404_bb0045","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1523\/JNEUROSCI.1547-09.2009","article-title":"The \"Down syndrome critical region\" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of down syndrome","volume":"29","author":"Belichenko","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173404_bb0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13293-015-0043-9","article-title":"Sex differences in protein expression in the mouse brain and their perturbations in a model of down syndrome","volume":"6","author":"Block","year":"2015","journal-title":"Biol. Sex Differ."},{"key":"10.1016\/j.pbb.2022.173404_bb0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neuroscience.2017.12.038","article-title":"The GABAAalpha5-selective modulator, RO4938581, rescues protein anomalies in the Ts65Dn mouse model of down syndrome","volume":"372","author":"Block","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2022.173404_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.pbb.2022.173404_bb0065","first-page":"61","article-title":"Dimethyl sulfoxide (DMSO): a review","volume":"76","author":"Brayton","year":"1986","journal-title":"Cornell Vet."},{"key":"10.1016\/j.pbb.2022.173404_bb0075","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrn896","article-title":"Neuroscience of attention-deficit\/hyperactivity disorder: the search for endophenotypes","volume":"3","author":"Castellanos","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pbb.2022.173404_bb0080","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nn.2600","article-title":"Olig1 and Olig2 triplication causes developmental brain defects in down syndrome","volume":"13","author":"Chakrabarti","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.pbb.2022.173404_bb0085","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1007\/s10803-019-04074-1","article-title":"Characteristics associated with autism spectrum disorder risk in individuals with down syndrome","volume":"49","author":"Channell","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pbb.2022.173404_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molcel.2013.09.009","article-title":"Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle","volume":"52","author":"Chen","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.pbb.2022.173404_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF02361154","article-title":"Behavioral assessment of the Ts65Dn mouse, a model for down syndrome: altered behavior in the elevated plus maze and open field","volume":"26","author":"Coussons-Read","year":"1996","journal-title":"Behav. Genet."},{"key":"10.1016\/j.pbb.2022.173404_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005983","article-title":"Hedgehog agonist therapy corrects structural and cognitive deficits in a down syndrome mouse model","volume":"5","author":"Das","year":"2013","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pbb.2022.173404_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-444-54299-1.00001-7","article-title":"Therapeutic approaches in the improvement of cognitive performance in down syndrome: past, present, and future","volume":"197","author":"De la Torre","year":"2012","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.pbb.2022.173404_bb0115","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mnfr.201300325","article-title":"Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in down syndrome mouse models and in humans","volume":"58","author":"De la Torre","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.pbb.2022.173404_bb0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0166-4328(97)81111-4","article-title":"Spatial memory deficits in segmental trisomic Ts65Dn mice","volume":"82","author":"Demas","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2022.173404_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072457","article-title":"Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting","volume":"8","author":"Eaton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2022.173404_bb0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0304-3940(95)12052-6","article-title":"A behavioral assessment of Ts65Dn mice: a putative down syndrome model","volume":"199","author":"Escorihuela","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pbb.2022.173404_bb0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.nbd.2011.04.011","article-title":"Comprehensive behavioral phenotyping of Ts65Dn mouse model of down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer","volume":"43","author":"Faizi","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173404_bb0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.febslet.2010.11.019","article-title":"Structural basis of CX-4945 binding to human protein kinase CK2","volume":"585","author":"Ferguson","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pbb.2022.173404_bb0150","article-title":"DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis","volume":"2","author":"Fern\u00e1ndez-Mart\u00ednez","year":"2015","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.pbb.2022.173404_bb0155","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1523\/JNEUROSCI.2658-14.2015","article-title":"Designer receptors enhance memory in a mouse model of down syndrome","volume":"35","author":"Fortress","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173404_bb0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40478-021-01237-z","article-title":"Forebrain shh overexpression improves cognitive function and locomotor hyperactivity in an aneuploid mouse model of down syndrome and its euploid littermates","volume":"9","author":"Gao","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.pbb.2022.173404_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106572","article-title":"Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of down syndrome","volume":"9","author":"Garcia-Cerro","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2022.173404_bb0170","first-page":"103","article-title":"Pharmacological approaches to improving cognitive function in down syndrome: current status and considerations","volume":"9","author":"Gardiner","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.pbb.2022.173404_bb0175","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jpeds.2011.06.007","article-title":"Direct health care costs of children and adolescents with down syndrome","volume":"159","author":"Geelhoed","year":"2011","journal-title":"J. Pediatr."},{"key":"10.1016\/j.pbb.2022.173404_bb0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s11689-017-9220-y","article-title":"Memory profiles in down syndrome across development: a review of memory abilities through the lifespan","volume":"10","author":"Godfrey","year":"2018","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.pbb.2022.173404_bb0185","doi-asserted-by":"crossref","first-page":"10426","DOI":"10.1038\/s41598-020-67133-z","article-title":"Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult down syndrome mice","volume":"10","author":"Goodlett","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2022.173404_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1750-3639.2010.00459.x","article-title":"Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome","volume":"21","author":"Guidi","year":"2011","journal-title":"Brain Pathol."},{"key":"10.1016\/j.pbb.2022.173404_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2008.11.006","article-title":"Dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous system","volume":"34","author":"Hanslick","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173404_bb0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tins.2011.11.001","article-title":"Trisomy 21 and early brain development","volume":"35","author":"Haydar","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.pbb.2022.173404_bb0205","doi-asserted-by":"crossref","first-page":"13333","DOI":"10.1073\/pnas.93.23.13333","article-title":"Developmental abnormalities and age-related neurodegeneration in a mouse model of down syndrome","volume":"93","author":"Holtzman","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2022.173404_bb0210","first-page":"839","article-title":"A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition","volume":"9","author":"Kim","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.pbb.2022.173404_bb0215","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.nbd.2011.10.009","article-title":"Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of down syndrome","volume":"45","author":"Kleschevnikov","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173404_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115215","article-title":"Skeletal dynamics of down syndrome: a developing perspective","volume":"133","author":"LaCombe","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.pbb.2022.173404_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02245742","article-title":"Ontogeny of muscimol effects on locomotor activity, habituation, and pain reactivity in mice","volume":"102","author":"Laviola","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173404_bb0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0166-4328(02)00026-8","article-title":"Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for down syndrome","volume":"134","author":"Martinez-Cue","year":"2002","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2022.173404_bb0235","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1601-183X.2005.00175.x","article-title":"Anxiety and panic responses to a predator in male and female Ts65Dn mice, a model for down syndrome","volume":"5","author":"Martinez-Cue","year":"2006","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.pbb.2022.173404_bb0240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000348677","article-title":"Novel PCR assay for determining the genetic sex of mice","volume":"7","author":"McFarlane","year":"2013","journal-title":"Sex Dev."},{"key":"10.1016\/j.pbb.2022.173404_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2011.12.034","article-title":"Developmentally altered inhibition in Ts65Dn, a mouse model of down syndrome","volume":"1440","author":"Mitra","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.pbb.2022.173404_bb0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pneurobio.2007.02.006","article-title":"Down syndrome gene dosage imbalance on cerebellum development","volume":"82","author":"Moldrich","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.pbb.2022.173404_bb0255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00496069","article-title":"GABA-mediated behavioral inhibition during ontogeny in the mouse","volume":"64","author":"Murphy","year":"1979","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173404_bb0260","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3758\/BF03337191","article-title":"Ontogeny of behavioral arousal in the mouse: effect of prior testing upon age of peak activity","volume":"7","author":"Nagy","year":"1976","journal-title":"Bull. Psychon. Soc."},{"key":"10.1016\/j.pbb.2022.173404_bb0265","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3758\/BF03333174","article-title":"Development of behavioral arousal and inhibition in the Swiss-Webster mouse","volume":"6","author":"Nagy","year":"1975","journal-title":"Bull. Psychon. Soc."},{"key":"10.1016\/j.pbb.2022.173404_bb0270","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/13543776.2017.1360285","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature","volume":"27","author":"Nguyen","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.pbb.2022.173404_bb0275","first-page":"108","article-title":"An appropriate loading control for western blot analysis in animal models of myocardial ischemic infarction","volume":"12","author":"Nie","year":"2017","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.pbb.2022.173404_bb0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.expneurol.2016.02.005","article-title":"Longitudinal measures of cognition in the Ts65Dn mouse: refining windows and defining modalities for therapeutic intervention in down syndrome","volume":"279","author":"Olmos-Serrano","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2022.173404_bb0285","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5607\/en.2013.22.4.244","article-title":"New perspectives of Dyrk1A role in neurogenesis and neuropathologic features of down syndrome","volume":"22","author":"Park","year":"2013","journal-title":"Exp Neurobiol"},{"key":"10.1016\/j.pbb.2022.173404_bb0290","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/bdra.20735","article-title":"Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004\u20132006","volume":"88","author":"Parker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.pbb.2022.173404_bb0295","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/j.ymthe.2021.05.023","article-title":"Restoring neuronal chloride homeostasis with anti-NKCC1 gene therapy rescues cognitive deficits in a mouse model of down syndrome","volume":"29","author":"Parrini","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pbb.2022.173404_bb0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","article-title":"The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review","volume":"463","author":"Prut","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173404_bb0310","series-title":"Image J","author":"Rasband","year":"1997"},{"key":"10.1016\/j.pbb.2022.173404_bb0315","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1037\/h0077471","article-title":"Emerging cholinergic mechanisms and ontogeny of response inhibition in the mouse","volume":"92","author":"Ray","year":"1978","journal-title":"J Comp Physiol Psychol"},{"key":"10.1016\/j.pbb.2022.173404_bb0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ng1095-177","article-title":"A mouse model for down syndrome exhibits learning and behaviour deficits","volume":"11","author":"Reeves","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.pbb.2022.173404_bb0325","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00335-011-9357-z","article-title":"Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn","volume":"22","author":"Reinholdt","year":"2011","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.pbb.2022.173404_bb0330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1097-0177(200002)217:2<137::AID-DVDY1>3.0.CO;2-N","article-title":"Parallels of craniofacial maldevelopment in down syndrome and Ts65Dn mice","volume":"217","author":"Richtsmeier","year":"2000","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.pbb.2022.173404_bb0335","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1534\/genetics.105.050898","article-title":"Perinatal loss of Ts65Dn Down syndrome mice","volume":"172","author":"Roper","year":"2006","journal-title":"Genetics"},{"key":"10.1016\/j.pbb.2022.173404_bb0340","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/hmg\/ddg217","article-title":"Global disruption of the cerebellar transcriptome in a down syndrome mouse model","volume":"12","author":"Saran","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.pbb.2022.173404_bb0345","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1128\/MCB.24.13.5821-5834.2004","article-title":"Dyrk1A potentiates steroid hormone-induced transcription via the chromatin remodeling factor Arip4","volume":"24","author":"Sitz","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.pbb.2022.173404_bb0350","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nbd.2014.04.016","article-title":"Excitation\/inhibition balance and learning are modified by Dyrk1a gene dosage","volume":"69","author":"Souchet","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173404_bb0355","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10519-006-9119-y","article-title":"Chronobiometry of behavioral activity in the Ts65Dn model of Down syndrome","volume":"37","author":"Stewart","year":"2007","journal-title":"Behav. Genet."},{"key":"10.1016\/j.pbb.2022.173404_bb0360","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.physbeh.2017.05.003","article-title":"Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes","volume":"177","author":"Stringer","year":"2017","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pbb.2022.173404_bb0365","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/mgg3.334","article-title":"Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve down syndrome deficits","volume":"5","author":"Stringer","year":"2017","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.pbb.2022.173404_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115367","article-title":"Interaction of sexual dimorphism and gene dosage imbalance in skeletal deficits associated with down syndrome","volume":"136","author":"Thomas","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.pbb.2022.173404_bb0375","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20150002","article-title":"DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing cyclin D3","volume":"212","author":"Thompson","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.pbb.2022.173404_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.682935","article-title":"Measuring anxiety-like behaviors in rodent models of traumatic brain injury","volume":"15","author":"Tucker","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2022.173404_bb0385","doi-asserted-by":"crossref","first-page":"8364","DOI":"10.1007\/s12035-019-01684-9","article-title":"Chronic Dyrk1 inhibition delays the onset of AD-like pathology in 3xTg-AD mice","volume":"56","author":"Velazquez","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pbb.2022.173404_bb0390","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1007\/s12035-017-0675-3","article-title":"Decreasing the expression of GABAA alpha5 subunit-containing receptors partially improves cognitive, electrophysiological, and morphological hippocampal defects in the Ts65Dn model of down syndrome","volume":"55","author":"Vidal","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pbb.2022.173404_bb0395","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1021\/pr1011476","article-title":"Coomassie staining as loading control in Western blot analysis","volume":"10","author":"Welinder","year":"2011","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.pbb.2022.173404_bb0400","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.1523\/JNEUROSCI.5746-12.2013","article-title":"Modeling transformations of neurodevelopmental sequences across mammalian species","volume":"33","author":"Workman","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173404_bb0405","doi-asserted-by":"crossref","DOI":"10.1186\/1687-9856-2010-652013","article-title":"The evaluation and followup of children referred to pediatric endocrinologists for short stature","volume":"2010","author":"Wyatt","year":"2010","journal-title":"Int. J. Pediatr. Endocrinol."},{"key":"10.1016\/j.pbb.2022.173404_bb0410","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1523\/JNEUROSCI.4711-09.2010","article-title":"Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells","volume":"30","author":"Yabut","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173404_bb0415","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58731","article-title":"Alterations of specific cortical GABAergic circuits underlie abnormal network activity in a mouse model of Down syndrome","volume":"9","author":"Zorrilla de San Martin","year":"2020","journal-title":"elife"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722000831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722000831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:43:18Z","timestamp":1758775398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722000831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":79,"alternative-id":["S0091305722000831"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173404","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173404"}}